ReviewHuman vaccines & immunotherapeutics2019
Current issues facing the introduction of human papillomavirus vaccine in China and future prospects.
Review in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Long-term effect of mobile phone-based education and influencing factors of willingness to receive HPV vaccination among female freshmen in Shanxi Province, China.Human vaccines & immunotherapeutics · 2022Trial
- Impact of web-based health education on HPV vaccination uptake among college girl students in Western and Northern China: a follow-up study.BMC women's health · 2022Trial
- Effect of an IMB Model-Based Education on the Acceptability of HPV Vaccination Among College Girls in Mainland China: A Cluster RCT.Cancer control : journal of the Moffitt Cancer CenterTrial
- Chinese caregivers' preferences and predicted uptake of HPV vaccination: a study protocol for two discrete choice experiments.BMJ open · 2026Article
- Breaking barriers: unraveling the impact of cultural beliefs and misconceptions on HPV vaccination uptake-the narrative review.Frontiers in public health · 2026Review
- Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study.Human vaccines & immunotherapeutics · 2025Review
- Willingness to pay and preference for HPV vaccine among parents in China: A study based on a multi-center cross-sectional survey.Human vaccines & immunotherapeutics · 2025Article
- Literature Review and Policy Recommendations for Single-Dose HPV Vaccination Schedule in China: Opportunities and Challenges.Vaccines · 2025Review
- Trends and urban-rural disparities in cervical cancer epidemiology in China, 2005-2018.Scientific reports · 2025Article
- Epidemiological characteristics of human papillomavirus in Guangzhou, China-A retrospective analysis of 76,898 cases.BMC public health · 2025Article
- A Computational Framework Analysis of Public Attitudes Toward Male Human Papillomavirus Infection and Its Vaccination in China: Based on Weibo Data.Healthcare (Basel, Switzerland) · 2025Article
- The impact of vaccine access difficulties on HPV vaccine intention and uptake among female university students in China.International journal for equity in health · 2025Article
- A pay-it-forward approach to improve feedback rate of HPV-based self-sampling in cervical cancer screening among women in ethnic minority regions of China: a randomized controlled trial protocol.Frontiers in psychiatry · 2025Article
- Parental willingness to pay and preference for human papillomavirus vaccine for girls aged 9-14 in subsidy scenarios in Shanghai, China.Human vaccines & immunotherapeutics · 2024Article
- Trends in Cancer Incidence and Potential Associated Factors in China.JAMA network open · 2024Article
- Exploring Cancer Incidence Trends by Age and Sex Among 14.14 Million Individuals in China From 2007 to 2021: Population-Based Study.JMIR public health and surveillance · 2024Article
- Attitudes toward an HPV vaccine for condyloma acuminata and willingness to undergo vaccination among STD clinic attendees in China: Focus on STI prevention with HPV vaccine.BMC public health · 2024Article
- Socioeconomic inequalities in human papillomavirus knowledge and vaccine uptake: evidence from a cross-sectional study in China.Frontiers in public health · 2024Article
- Trends in the Disease Burden and Risk Factors of Women's Cancers in China From 1990 to 2019.International journal of public health · 2024Article
- Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of human papillomavirus (HPV) vaccination in China aims to prevent HPV infection in all women. The issues that China might face include high cost of vaccines made in other countries, shortage in HPV vaccine supply, negative events attributed to vaccination (whether justified or not) that jeopardizes the general public's confidence in the HPV vaccine, cultural and literacy barriers, and sensitivity to receiving a vaccine for a sexually transmitted disease. Ensuring the effective delivery of the HPV vaccine in China, a country with vast economic, geographical, and cultural complexities, will require a commitment of significant resources. In light of the high price of imported vaccines, the availability of locally manufactured HPV vaccines would greatly facilitate the national HPV vaccination program. New evidence supporting the efficacy of a two-dose regime in younger adolescents would also be advantageous in terms of affordability and logistical simplicity of vaccine administration. Furthermore, it would potentially enhance the compliance and uptake, especially for hard to reach women in remote regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.